ID11916

ID11916 is an orally active androgen receptor (AR) antagonist and a phosphodiesterase 5 (PDE5) inhibitor. ID11916 blocks androgen binding to AR, nuclear translocation, and androgen-dependent transcriptional activity of AR, while increasing intracellular cGMP levels and activating PKG via inhibition. ID11916 shows potent anti-cancer effect in prostate cancer cell lines VCaP and 22Rv1 and in AR-positive breast cancer cell lines SK-BR-3[1].

Product Specifications

CAS Number

[2785317-21-5]

UNSPSC

12352005

Target

Androgen Receptor; Phosphodiesterase (PDE)

Related Pathways

Metabolic Enzyme/Protease; Vitamin D Related/Nuclear Receptor

Applications

Cancer-programmed cell death

Field of Research

Cancer

Smiles

O=C1C(C)(N(C(N1C2=CN=C(C(C(F)(F)F)=C2)C#N)=S)C3=CC=C(C(C4=NN5C(C(N4)=O)=C(N=C5CCC)C)=C3)OCC)C

Molecular Formula

C29H27F3N8O3S

Molecular Weight

624.64

References & Citations

[1]Jeong Eun Kim, et al. Abstract 5601: ID11916, a novel androgen receptor antagonist with cGMP-dependent protein kinase activation for next-generation therapeutics in AR positive tumors. Cancer Res (2025) 85 (8_Supplement_1) : 5601.